Gilead Sciences, Inc. (NASDAQ:GILD) – Stock analysts at Leerink Swann upped their Q4 2017 earnings estimates for Gilead Sciences in a research note issued on Monday. Leerink Swann analyst G. Porges now expects that the biopharmaceutical company will post earnings per share of $2.09 for the quarter, up from their prior forecast of $1.94. Leerink Swann currently has a “Market Perform” rating on the stock. Leerink Swann also issued estimates for Gilead Sciences’ FY2021 earnings at $8.10 EPS.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $2.18 by $0.02. The business had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.66 billion. Gilead Sciences had a net margin of 43.42% and a return on equity of 76.64%.

COPYRIGHT VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/07/19/q4-2017-earnings-estimate-for-gilead-sciences-inc-gild-issued-by-leerink-swann.html.

GILD has been the topic of a number of other reports. BMO Capital Markets reaffirmed a “hold” rating and issued a $76.00 target price (up from $75.00) on shares of Gilead Sciences in a research report on Wednesday, May 3rd. Cowen and Company reaffirmed an “outperform” rating and issued a $90.00 target price on shares of Gilead Sciences in a research report on Wednesday, July 5th. J P Morgan Chase & Co reaffirmed an “overweight” rating and issued a $82.00 target price on shares of Gilead Sciences in a research report on Thursday, April 6th. Morgan Stanley reaffirmed an “equal weight” rating on shares of Gilead Sciences in a research report on Tuesday, July 11th. Finally, Credit Suisse Group reaffirmed an “outperform” rating and issued a $79.00 target price on shares of Gilead Sciences in a research report on Monday, May 15th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company. Gilead Sciences has a consensus rating of “Buy” and an average price target of $80.24.

Gilead Sciences (GILD) traded up 1.025% during midday trading on Wednesday, reaching $72.425. 3,463,433 shares of the company’s stock were exchanged. The company has a market cap of $94.64 billion, a price-to-earnings ratio of 7.654 and a beta of 1.21. The firm has a 50-day moving average price of $67.84 and a 200 day moving average price of $68.56. Gilead Sciences has a 12-month low of $63.76 and a 12-month high of $88.85.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 29th. Investors of record on Friday, June 16th were issued a $0.52 dividend. The ex-dividend date of this dividend was Wednesday, June 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.90%. Gilead Sciences’s payout ratio is currently 21.99%.

In related news, EVP Gregg H. Alton sold 5,000 shares of Gilead Sciences stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.06, for a total value of $355,300.00. Following the completion of the sale, the executive vice president now directly owns 102,988 shares in the company, valued at $7,318,327.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the sale, the insider now owns 3,199,969 shares of the company’s stock, valued at $227,197,799. The disclosure for this sale can be found here. Insiders sold 88,276 shares of company stock valued at $6,230,610 over the last 90 days. 1.30% of the stock is currently owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in GILD. Keel Point LLC increased its stake in Gilead Sciences by 0.4% in the first quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock valued at $211,000 after buying an additional 11 shares during the last quarter. West Oak Capital LLC increased its stake in Gilead Sciences by 0.7% in the second quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock valued at $330,000 after buying an additional 32 shares during the last quarter. Bluestein R H & Co. increased its stake in Gilead Sciences by 1.2% in the fourth quarter. Bluestein R H & Co. now owns 3,665 shares of the biopharmaceutical company’s stock valued at $262,000 after buying an additional 45 shares during the last quarter. Westover Capital Advisors LLC increased its stake in Gilead Sciences by 0.8% in the first quarter. Westover Capital Advisors LLC now owns 5,563 shares of the biopharmaceutical company’s stock valued at $378,000 after buying an additional 46 shares during the last quarter. Finally, Abner Herrman & Brock LLC increased its stake in Gilead Sciences by 0.5% in the first quarter. Abner Herrman & Brock LLC now owns 10,202 shares of the biopharmaceutical company’s stock valued at $693,000 after buying an additional 50 shares during the last quarter. Hedge funds and other institutional investors own 74.03% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.